Moore Capital Management’s Regenxbio RGNX Stock Holding History

Moore Capital Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-200,000	Closed	-$2.88M	–	780
2025 Q4	$2.88M	Buy	200,000 +50,000	+33%	+$623K	0.04%	329
2025 Q3	$1.45M	Hold	150,000	–	–	0.02%	388
2025 Q2	$1.23M	Buy	150,000 +50,000	+50%	+$419K	0.02%	358
2025 Q1	$715K	Hold	100,000	–	–	0.01%	337
2024 Q4	$773K	Hold	100,000	–	–	0.01%	396
2024 Q3	$1.05M	Hold	100,000	–	–	0.02%	348
2024 Q2	$1.17M	Hold	100,000	–	–	0.02%	300
2024 Q1	$2.11M	Buy	+100,000	New	+$1.78M	0.03%	262

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Moore Capital Management's RGNX Position: Q1 2026 in Review

Moore Capital Management sold out of Regenxbio (RGNX) in Q1 2026, closing a stake of 200,000 shares — an estimated $2.88M sold.

Moore Capital Management first reported a position in RGNX in Q1 2024 and held it in 8 quarters. The position peaked at $2.88M in Q4 2025. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.

Moore Capital Management reported no remaining Regenxbio position as of Q1 2026 after selling out during the quarter.
Moore Capital Management sold 200,000 Regenxbio shares in Q1 2026, an estimated $2.88M.
Moore Capital Management first reported a position in Regenxbio in Q1 2024 and held it in 8 quarters.
Moore Capital Management's Regenxbio position peaked at $2.88M in Q4 2025.
178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.

Based on Moore Capital Management's 13F filing for Q1 2026, filed 15 May 2026.